Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 8, 2000, Pages 2767-2774

  Pasquali, Renato ^a   Gambineri, Alessandra ^a   Biscotti, Domenico ^a   Vicennati, Valentina ^a   Gagliardi, Lorenza ^a   Colitta, Donatella ^a   Fiorini, Stefania ^a   Cognigni, Graciela Estela ^b   Filicori, Marco ^b   Morselli Labate, Antonio Maria ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FOLLITROPIN; INSULIN; LEPTIN; LUTEINIZING HORMONE; METFORMIN; PLACEBO; PRASTERONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HIRSUTISM; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LONG TERM CARE; LOW CALORY DIET; MENSTRUAL CYCLE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TISSUE DISTRIBUTION;

FALLOPIA;

EID: 17744400090     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.85.8.6738     Document Type: Article

References (44)

1. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
2. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women
3. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome
4. Polycystic ovary syndrome
5. On the paradox of insulin-induced hyperandrogenism in insulin-resistant state
6. Decrease of ovarian cytochrome P45017α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
7. Sex hormone-binding globulin changes with androgen replacement
8. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin
9. On the regulation of sex-hormone-binding globulin: Challenge of an old dogma and outlines of an alternative mechanism
10. Biology of regional body fat distribution: Relationship to non-insulin dependent diabetes mellitus
11. Relationship of androgenic activity to body fat topography, fat cell morphology and metabolic aberrations in premenopausal women
12. Characterization of obese women with reduced sex hormone-binding globulin concentrations
13. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy
14. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome
15. Hyperandrogenicity in women-a prediabetic condition?
16. Exogenous androgens influence body composition and regional body fat distribution in obese post-menopausal women-a clinical research center study
17. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss
18. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
19. 17 α-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss
20. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome
21. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
22. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
23. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
24. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
25. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome
26. Preventing and managing the global epidemic
27. Nitrendipine treatment in women with polycystic ovarian syndrome: Evidence for a lack of effects of calcium channel blockers on insulin, androgens, and sex hormone-binding globulin
28. Ultrasonic findings in polycystic ovarian diseasae
29. Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels
30. Techniques for the measurement of visceral fat: A practical guide
31. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment
32. Robust test for equality of variance
33. Insulin resistance in obese and nonobese man
34. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women
35. Treatment of obesity: Conventional programs and fat diets
36. Insulin and androgen relationships with abdominal body fat distribution in women with and without hyperandrogenism
37. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome
38. Serum immunoreactive-leptin concentrations in normal-weight and obese humans
39. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome
40. Nutritional regulation of leptin in humans